Private Market View

Qiyuyuan Biotechnology

Changsha, China · Founded 2025 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$140K
Last round

Key facts

  • It has raised $140K; the latest was Seed Round ($140K) in Dec 2025.
  • Notable investors include Hunan Lushan Technology Investment.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Qiyuyuan Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Qiyuyuan Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Qiyuyuan Biotechnology

Manufacturer of bioengineered collagen materials designed to replicate human extracellular matrix for medical and aesthetic applications. The company offers physically induced human collagen fiber networks with stem cell-derived structures and high biocompatibility, enabling medical aesthetics providers, healthcare institutions, and research organizations to achieve effective tissue repair and regenerative outcomes.

Sector
Healthcare
HQ
Changsha, China
Founded
2025
Ownership
Privately Held (backing)
PA Mark — not yet priced

Qiyuyuan Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Qiyuyuan Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Qiyuyuan Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.